Viveve to Announce Financial Results for Fourth Quarter and Year End 2016
SUNNYVALE, CA -- (Marketwired) -- 02/09/17 -- Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, will announce financial results for the fourth quarter 2016 and the full year ending December 31, 2016 on Thursday, February 16, 2017 after market close. The Company will also host a live conference call to discuss these financial results and provide an update on corporate and commercial developments. Participating on the call will be Patricia Scheller, chief executive officer, and Scott Durbin, chief financial officer. Following management's formal remarks, there will be a question and answer session.
The conference call is scheduled to begin at 5:00 p.m. ET on Thursday, February 16, 2017. The conference call can be accessed at http://dpregister.com/10100786. The dial-in telephone number will be provided upon registration, either in advance of or at the time of the conference call. The conference call will be archived on the company's website at www.ir.viveve.com.
Viveve Medical, Inc. is a women's health and wellness company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented GENEVEVE™ treatment, incorporates clinically-proven, cryogen-cooled, monopolar radiofrequency (CMRF) to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in one 30-minute in-office session.
In the United States, the GENEVEVE treatment is cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis. Consistent with approvals in many countries internationally, Viveve is currently seeking regulatory clearance in the United States for improvement in sexual function. For more information visit Viveve's website at www.viveve.com.
Safe Harbor Statement
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Viveve is a registered trademark of Viveve, Inc.
Geneveve is a trademark of Viveve, Inc.
Investor Relations contact:
Amato and Partners, LLC
90 Park Avenue, 17th Floor
New York, NY 10016
Berry & Company Public Relations
Source: Viveve Medical, Inc.
Released February 9, 2017